{"id":53128,"date":"2023-01-20T07:04:14","date_gmt":"2023-01-20T06:04:14","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/imcas-2023-galderma-to-share-latest-data-demonstrating-high-aesthetic-improvement-and-patient-satisfaction-across-its-innovative-portfolio\/"},"modified":"2023-01-20T07:04:14","modified_gmt":"2023-01-20T06:04:14","slug":"imcas-2023-galderma-to-share-latest-data-demonstrating-high-aesthetic-improvement-and-patient-satisfaction-across-its-innovative-portfolio","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/imcas-2023-galderma-to-share-latest-data-demonstrating-high-aesthetic-improvement-and-patient-satisfaction-across-its-innovative-portfolio\/","title":{"rendered":"IMCAS 2023: Galderma to Share Latest Data Demonstrating High Aesthetic Improvement and Patient Satisfaction Across Its Innovative Portfolio"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\nGalderma will share exciting results from the Sculptra<sup>\u00ae<\/sup> Cheek Wrinkle study showing the long-lasting effectiveness and safety of Sculptra, as well as high aesthetic improvement and patient satisfaction over two years<sup>i<\/sup>\n<\/li>\n<li>\nThe company will also present 10 research posters, including positive outcomes from the Alluzience<sup>\u00ae<\/sup> STAR study. This study shows high patient satisfaction and investigator preference for Alluzience over powder solutions and long duration of effect at six months<sup>ii<\/sup>\n<\/li>\n<li>\nTwo symposia will build on Galderma\u2019s Holistic Individualized Treatment (HIT\u2122) approach through programs Kiss &amp; Smile\u2122 and Balanced Profile\u2122, and on another new solution offering an innovative long-term treatment approach\n<\/li>\n<\/ul>\n<p>ZUG, Switzerland&#8211;(BUSINESS WIRE)&#8211;Galderma will be showcasing the latest updates from across its portfolio at the International Master Course on Aging Science (IMCAS) World Congress 2023 in Paris from January 26-28, 2023. Events will include several \u2018meet the expert\u2019 sessions and interactive booth activities. In addition, Galderma will share 10 research posters and host two symposia, featuring data from its broad, highly differentiated portfolio of neuromodulators, biostimulators and fillers. Presenters and contributors will draw from the company\u2019s research into serious skin conditions, such as rosacea and actinic keratosis.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20230119005530\/en\/1690638\/5\/GALDERMA_LOGO_BLACK_RGB.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230119005530\/en\/1690638\/21\/GALDERMA_LOGO_BLACK_RGB.jpg\"><\/a><\/p>\n<p>\nGalderma is the only pure-play dermatology category leader, with more than 40 years of heritage in dermatology. Its significant presence at IMCAS underscores its commitment to delivering science, innovation and a premium experience for physicians, consumers and patients throughout the treatment journey. Galderma is a leader in bringing cutting-edge products to market and in providing the scientific community with individualized treatment approaches, training and business support.\n<\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignc\">\n<tr>\n<td class=\"bwpadl0 bwrowaltcolor0 bwvertalignm\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<p class=\"bwalignc bwcellpmargin\">\n\u201cThe strength and span of our presence at IMCAS 2023 reinforce our enduring commitment to providing physicians, consumers and patients with truly innovative and individualized solutions.<br \/>\n<br \/>We look forward to connecting with the dermatology community at the congress.<br \/>\n<br \/>We will not only share our latest data but also support physicians as they take the best approach in education, assessment and technique.\u201d\n<\/p>\n<p class=\"bwalignc bwcellpmargin\">\n\u00a0\n<\/p>\n<p class=\"bwalignc bwcellpmargin\">\n<b>BALDO SCASSELLATI SFORZOLINI, M.D., Ph.D.<br \/>\n<br \/><\/b><b>GLOBAL HEAD OF R&amp;D<br \/>\n<br \/><\/b><b>GALDERMA<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>\n<b>Presenting the latest in clinical findings and educational efforts<\/b>\n<\/p>\n<p>\nGalderma will be sharing important data at IMCAS on Sculptra<sup>\u00ae<\/sup> (injectable poly-L-lactic acid, PLLA-SCA). This is the first and only U.S. Food and Drug Administration (FDA)-approved PLLA facial injectable treatment that helps stimulate the skin\u2019s type I collagen production.<sup>iii,iv<\/sup> Sculptra helps restore fullness and firmness to areas of the face that become loose or saggy. The results of the innovative Sculptra Cheek Wrinkle study, which were measured using state-of-the-art technology, show the early onset, long-lasting effectiveness and safety of the treatment for cheek wrinkle correction over 24 months. These findings were complemented by high aesthetic improvement, high subject satisfaction with cheek appearance, and improvement in skin quality parameters including radiance and skin firmness (tightness) after treatment.<sup>i<\/sup>\n<\/p>\n<p>\nAdditional exciting data will be presented for Galderma\u2019s neuromodulators, in particular for Alluzience<sup>\u00ae<\/sup> (abobotulinumtoxinA solution), including the latest data from Alluzience\u2019s first phase IV study, STAR. Approved in Europe in June 2021, Alluzience is Europe\u2019s first ready-to-use liquid neuromodulator for the treatment of moderate to severe glabellar lines (frown lines). Results from the unique STAR study show high patient satisfaction, with most investigators preferring Alluzience to powder solutions. Both investigators and patients also reported long-duration aesthetic improvement following a six-month follow-up period.<sup>ii<\/sup>\n<\/p>\n<p>\nGalderma\u2019s symposia at IMCAS highlight its dedication to providing not only innovative products but also cutting-edge approaches to support physician assessment and technique.\n<\/p>\n<p>\nThe first symposium builds on Galderma\u2019s Holistic Individualized Treatment (HIT\u2122) series with a focus on two new programs: <b>HIT Kiss &amp; Smile\u2122 and Balanced Profile\u2122<\/b>.<b> <\/b>HIT is a patient-centric, science-based, individualized treatment approach that enables injectors to leverage their expertise with the renowned Galderma portfolio and optimize aesthetic outcomes while prioritizing patient satisfaction. The event is taking place in the Amphitheatre Bleu, Level 2 on Friday, January 27, from 8:30 to 10:00 AM CET.\n<\/p>\n<p>\nThe second symposium, <b>Our Aesthetic Lives: A long-term journey into aesthetic treatments,<\/b> will deep-dive into the aesthetic lives of patients and the medical professionals who treat them as they shape the future of this field. It will take place in the Amphitheatre Bleu, Level 2 on Friday, January 27, from 4:00 to 6:00 PM CET.\n<\/p>\n<p>\n<b>Showcasing cutting-edge research with 10 research posters<\/b>\n<\/p>\n<p>\n<b><i>Neuromodulators<\/i><\/b>\n<\/p>\n<p>\nGalderma will be sharing several updates on its neuromodulators, Alluzience and Azzalure<sup>\u00ae<\/sup> (abobotulinumtoxinA), including:\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nReady-to-use abobotulinumtoxinA solution versus powder onabotulinumtoxinA for treating glabellar lines: Subjects\u2019 and Investigators\u2019 experiences <sup>ii<\/sup>\n<\/li>\n<li>\nSubject and physician satisfaction with abobotulinumtoxinA for glabellar line treatment in a real-world study in Chinese subjects<sup>v<\/sup>\n<\/li>\n<li>\nHow glabellar line severity at baseline can affect efficacy in neurotoxin trials<sup>vi<\/sup>\n<\/li>\n<\/ul>\n<p>\n<b><i>Biostimulators<\/i><\/b>\n<\/p>\n<p>\nPosters on Sculptra, the first and only U.S. FDA-approved PLLA facial injectable treatment, include:\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nEffectiveness and safety of cheek wrinkle correction using a biostimulatory poly-L-lactic acid injectable implant \u2013 clinical study data up to 24 months <sup>i<\/sup>\n<\/li>\n<li>\nProduct manufacturing process for poly-L-lactic acid (PLLA-SCA)<sup>vii<\/sup>\n<\/li>\n<li>\nSkin movement and volume changes with poly-L-lactic acid (PLLA-SCA) injectable implant: a subgroup analysis of the cheek wrinkle trial<sup>viii<\/sup>\n<\/li>\n<\/ul>\n<p>\n<b><i>Fillers<\/i><\/b>\n<\/p>\n<p>\nGalderma will also be sharing the latest data on its portfolio of fillers, including Restylane<sup>\u00ae<\/sup> Defyne for chin. Restylane Defyne has demonstrated results across a wide range of participants, including participants with all skin types, males, and those over the age of 52.<sup>ix<\/sup> Posters include:\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nImprovement of chin retrusion in Chinese subjects using a hyaluronic acid filler: a randomized, controlled, evaluator-blinded study<sup>x<\/sup>\n<\/li>\n<li>\nDifferentiation of NASHA<sup>TM<\/sup> and OBT<sup> TM<\/sup> hyaluronic acid gels according to firmness and flexibility and associated clinical significance<sup>xi<\/sup>\n<\/li>\n<\/ul>\n<p>\n<b><i>Actinic keratosis and rosacea<\/i><\/b>\n<\/p>\n<p>\nFor decades, Galderma has been researching these serious and often severe skin conditions that affect a significant cross-section of society, reflecting its expertise and demonstrating its commitment to advancing dermatology for every skin story. Posters include:\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nCosmetic outcomes in patient-centered management of AK \u2013 Personalizing Actinic Keratosis Treatment (PAKT) expert consensus<sup>xii<\/sup>\n<\/li>\n<li>\nA customized skin care routine benefits patients with severe rosacea under combination therapy with ivermectin 1% cream and doxycycline 40-mg or ivermectin and placebo<sup>xiii<\/sup>\n<\/li>\n<\/ul>\n<p>\n<b>About Alluzience<sup>\u00ae<\/sup><\/b>\n<\/p>\n<p>\nAlluzience (abobotulinumtoxinA solution) is the first ready-to-use BoNT-A liquid neuromodulator formulation to be introduced in Europe. Alluzience is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines seen at maximum frown in adult patients under 65 years, when the severity of these lines has an important psychological impact on the patient.<sup>xiv <\/sup>It should only be administered by a physician with appropriate qualifications and expertise in this treatment using the required equipment.<sup>xiv<\/sup> Dosing and treatment intervals depend on assessment of the individual patient\u2019s response.<sup>xiv<\/sup> The treatment interval should be no more frequent than every three months.<sup>xiv<\/sup> For more information, please see the Summary of Product Characteristics.<sup>xiv<\/sup>\n<\/p>\n<p>\nAlluzience is a product under license from Ipsen. Alluzience is a registered trademark of Ipsen. Galderma has an exclusive license from Ipsen to develop, promote and distribute Alluzience in the approved indication in Europe (excluding Greece, Lithuania, Estonia, Latvia, Hungary).\n<\/p>\n<p>\n<b>About Azzalure<sup>\u00ae<\/sup> \/ Dysport<sup>\u00ae<\/sup><\/b>\n<\/p>\n<p>\nDysport (abobotulinumtoxinA) is a prescription injection indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with procerus and corrugator muscle activity in adult patients less than 65 years of age, the treatment of adults with cervical dystonia, the treatment of upper limb spasticity in adults, and the treatment of lower limb spasticity in pediatric patients two years of age and older.<sup>xv<\/sup> Dysport is also marketed as Azzalure in the European Union for the treatment of glabellar lines and lateral canthal lines. Dysport has more than 30 years of clinical experience globally for therapeutic indications and 13 years for aesthetics indications, with extensive clinical evidence of safety and efficacy. It is licensed for aesthetic indications in more than 85 markets worldwide, Dysport is one of the world\u2019s leading brands of aesthetic neuromodulators with over 100 million treatments delivered in the aesthetics indications to date.\n<\/p>\n<p>\nDysport is a product under license from Ipsen and is manufactured by them. Since 2009, Galderma and Ipsen have had a strategic partnership under which Galderma has promoted and distributed Ipsen\u2019s botulinum toxin type A products in aesthetic indications. The Ipsen-Galderma strategic partnership now covers China, the United States, Europe and the Middle East, Australia, South Korea, Canada, Brazil, Argentina and certain other countries. Ipsen continues to promote Dysport within certain therapeutic indications in countries around the world. For more information on Ipsen, visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.ipsen.com%2F&amp;esheet=53281837&amp;newsitemid=20230119005530&amp;lan=en-US&amp;anchor=www.ipsen.com&amp;index=1&amp;md5=321c4f1383851fe3a5c7515feb87e614\" rel=\"nofollow noopener\" shape=\"rect\">www.ipsen.com<\/a>.\n<\/p>\n<p>\n<b>About Galderma\u2019s Restylane<sup>\u00ae<\/sup> portfolio<\/b>\n<\/p>\n<p>\nRESTYLANE is the original non-animal stabilized hyaluronic acid filler with over 26 years of achievement and over 55 million treatments worldwide. NASHA\u2122 and OBT\u2122 technologies make RESTYLANE the world\u2019s most diverse range of fillers to deliver truly individualized results.<sup>xvi,xvii<\/sup>\n<\/p>\n<p>\nThe RESTYLANE portfolio of products includes RESTYLANE, RESTYLANE<sup>\u00ae<\/sup> LYFT<sup>TM<\/sup>, RESTYLANE<sup>\u00ae<\/sup> KYSSE<sup>TM<\/sup>, RESTYLANE<sup>\u00ae<\/sup> VOLYME<sup>TM<\/sup>, RESTYLANE<sup>\u00ae<\/sup> DEFYNE<sup>TM<\/sup>, RESTYLANE<sup>\u00ae<\/sup> REFYNE<sup>TM<\/sup>, RESTYLANE<sup>\u00ae<\/sup> EYELIGHT<sup>TM<\/sup> and RESTYLANE<sup>\u00ae<\/sup> SKINBOOSTERS VITAL<sup>TM<\/sup>.\n<\/p>\n<p>\n<b>About Sculptra<sup>\u00ae<\/sup><\/b>\n<\/p>\n<p>\nSCULPTRA is the first and original injectable collagen stimulator containing microparticles of unique poly-L-lactic acid (PLLA-SCA) which gradually revitalizes the skin\u2019s structural foundation, providing long-term results for more than two years.<sup>xviii<\/sup> SCULPTRA was first approved in 1999 in Europe, and it is currently available in more than 40 countries globally.\n<\/p>\n<p>\nSCULPTRA works to stimulate the skin\u2019s own collagen production<sup>xix<\/sup> to provide firm and radiant skin. It is suitable for increasing the volume of depressed areas, particularly to correct skin depressions such as skin creases, wrinkles, folds, and scars, and for signs of skin aging.<sup>xx<\/sup>\n<\/p>\n<p>\n<b>About Galderma<\/b>\n<\/p>\n<p>\nGalderma is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermo-Cosmetics and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body\u2019s largest organ \u2013 the skin \u2013 meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we\u2019re in shapes our lives, we are advancing dermatology for every skin story. Galderma\u2019s portfolio of flagship brands includes Restylane, Dysport, Azzalure, Alluzience and Sculptra in Injectable Aesthetics; Soolantra<sup>\u00ae<\/sup>, Epiduo<sup>\u00ae<\/sup>, Differin<sup>\u00ae<\/sup>, Aklief<sup>\u00ae<\/sup>, Epsolay<sup>\u00ae<\/sup>, Twyneo<sup>\u00ae<\/sup>, Oracea<sup>\u00ae<\/sup>, Metvix<sup>\u00ae<\/sup>, Benzac<sup>\u00ae<\/sup> and Loceryl<sup>\u00ae<\/sup> in Therapeutic Dermatology; and Cetaphil<sup>\u00ae<\/sup> and Alastin<sup>\u00ae<\/sup> in Dermo-cosmetics. For more information, visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.galderma.com%2F&amp;esheet=53281837&amp;newsitemid=20230119005530&amp;lan=en-US&amp;anchor=www.galderma.com.&amp;index=2&amp;md5=114671d03293c29f82c89971ca687903\" rel=\"nofollow noopener\" shape=\"rect\">www.galderma.com.<\/a>\n<\/p>\n<p>\n<b>References<\/b>\n<\/p>\n<p>\n<sup>i<\/sup> Fabi S. Poster presented at IMCAS 2023.<br \/>\n<br \/><sup>ii<\/sup> Arne Gerber P. Poster presented at IMCAS 2023.<br \/>\n<br \/><sup>iii<\/sup> Sculptra injectable poly-L-lactic acid. Instructions for Use. Galderma Laboratories. 2023.<br \/>\n<br \/><sup>iv<\/sup> Stein P. et al. J Dermatol Sci. 2015;78:26-33.<br \/>\n<br \/><sup>v<\/sup> Song W. Poster presented at IMCAS 2023.<br \/>\n<br \/><sup>vi<\/sup> Kaufman-Janette J. Poster presented at IMCAS 2023.<br \/>\n<br \/><sup>vii<\/sup> Morgan P. Poster presented at IMCAS 2023.<br \/>\n<br \/><sup>viii<\/sup> Fabi S. Poster presented at IMCAS 2023.<br \/>\n<br \/><sup>ix<\/sup> Data on file. 43USCH1702 Clinical Study Report. Fort Worth, TX: Galderma Laboratories, L.P., 2020.<br \/>\n<br \/><sup>x<\/sup> Xie Y. Poster presented at IMCAS 2023.<br \/>\n<br \/><sup>xi<\/sup> \u00d6hrlund A. Poster presented at IMCAS 2023.<br \/>\n<br \/><sup>xii<\/sup> Haedersdal M. Poster presented at IMCAS 2023.<br \/>\n<br \/><sup>xiii<\/sup> Schaller M. Poster presented at IMCAS 2023.<br \/>\n<br \/><sup>xiv<\/sup> Alluzience Summary of Product Characteristics, 2022.<br \/>\n<br \/><sup>xv<\/sup> Dysport Summary of Product Characteristics, 2022<br \/>\n<br \/><sup>xvi<\/sup> Data on file (MA-33939).<br \/>\n<br \/><sup>xvii<\/sup> \u00d6hrlund A. Poster presented at AMWC 2019.<br \/>\n<br \/><sup>xviii<\/sup> Brown SA et al. Plast Reconstr Surg 2011;127(4):1684\u201392.<br \/>\n<br \/><sup>xix<\/sup> Bohnert K et al. Plast Reconstr Surg 2019;127(4):1684\u201392.<br \/>\n<br \/><sup>xx<\/sup> Sculptra IFU. 2018.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>For further information:<\/b><br \/>Christian Marcoux, M.Sc.<br \/>\n<br \/>Chief Communications Officer<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#97;&#105;l&#x74;&#x6f;&#58;c&#x68;&#x72;&#105;s&#x74;&#x69;&#97;n&#x2e;&#x6d;&#97;r&#x63;&#x6f;&#117;x&#x40;&#x67;&#97;&#108;d&#x65;&#x72;&#109;a&#x2e;&#x63;&#111;m\" rel=\"nofollow noopener\" shape=\"rect\">&#x63;&#x68;&#x72;&#x69;&#x73;&#x74;&#x69;&#97;&#110;&#46;&#109;&#97;rcou&#x78;&#x40;&#x67;&#x61;&#x6c;&#x64;&#x65;&#x72;&#109;&#97;&#46;&#99;&#111;m<\/a><br \/>+41 76 315 26 50<\/p>\n<p>Rachel Mooney<br \/>\n<br \/>Global Franchise Communications<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;i&#108;&#x74;o&#58;&#x72;a&#x63;&#x68;&#101;&#x6c;&#46;&#109;&#x6f;o&#110;&#x65;y&#x40;&#x67;&#97;&#x6c;&#x64;&#101;&#x72;m&#97;&#x2e;c&#111;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#x72;&#97;c&#x68;&#x65;&#108;&#46;&#x6d;&#111;o&#x6e;&#x65;&#121;&#64;&#x67;&#97;l&#x64;&#x65;&#114;m&#x61;&#x2e;&#99;&#x6f;&#x6d;<\/a><br \/>+41 76 261 64 41\n<\/p>\n<p>\nS\u00e9bastien Cros<br \/>\n<br \/>Corporate Communications Director<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#97;&#x69;l&#116;&#x6f;&#x3a;S&#101;&#x62;&#x61;s&#116;&#x69;&#x61;n&#46;&#x63;&#x72;o&#115;&#x40;&#x67;a&#108;&#x64;e&#114;&#109;&#x61;&#46;&#99;&#x6f;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#x53;&#x65;&#x62;&#x61;&#x73;&#116;&#105;&#97;&#110;&#46;cr&#x6f;&#x73;&#x40;&#x67;&#x61;&#x6c;&#100;&#101;&#114;ma&#46;&#x63;&#x6f;&#x6d;<\/a><br \/>+41 79 529 59 85\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Galderma will share exciting results from the Sculptra\u00ae Cheek Wrinkle study showing the long-lasting effectiveness and safety of Sculptra, as well as high aesthetic improvement and patient satisfaction over two yearsi The company will also present 10 research posters, including positive outcomes from the Alluzience\u00ae STAR study. This study shows high patient satisfaction and investigator &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/imcas-2023-galderma-to-share-latest-data-demonstrating-high-aesthetic-improvement-and-patient-satisfaction-across-its-innovative-portfolio\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-53128","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>IMCAS 2023: Galderma to Share Latest Data Demonstrating High Aesthetic Improvement and Patient Satisfaction Across Its Innovative Portfolio - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/imcas-2023-galderma-to-share-latest-data-demonstrating-high-aesthetic-improvement-and-patient-satisfaction-across-its-innovative-portfolio\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IMCAS 2023: Galderma to Share Latest Data Demonstrating High Aesthetic Improvement and Patient Satisfaction Across Its Innovative Portfolio - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Galderma will share exciting results from the Sculptra\u00ae Cheek Wrinkle study showing the long-lasting effectiveness and safety of Sculptra, as well as high aesthetic improvement and patient satisfaction over two yearsi The company will also present 10 research posters, including positive outcomes from the Alluzience\u00ae STAR study. This study shows high patient satisfaction and investigator ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/imcas-2023-galderma-to-share-latest-data-demonstrating-high-aesthetic-improvement-and-patient-satisfaction-across-its-innovative-portfolio\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-20T06:04:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230119005530\/en\/1690638\/21\/GALDERMA_LOGO_BLACK_RGB.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"9 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/imcas-2023-galderma-to-share-latest-data-demonstrating-high-aesthetic-improvement-and-patient-satisfaction-across-its-innovative-portfolio\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/imcas-2023-galderma-to-share-latest-data-demonstrating-high-aesthetic-improvement-and-patient-satisfaction-across-its-innovative-portfolio\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"IMCAS 2023: Galderma to Share Latest Data Demonstrating High Aesthetic Improvement and Patient Satisfaction Across Its Innovative Portfolio\",\"datePublished\":\"2023-01-20T06:04:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/imcas-2023-galderma-to-share-latest-data-demonstrating-high-aesthetic-improvement-and-patient-satisfaction-across-its-innovative-portfolio\\\/\"},\"wordCount\":1871,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/imcas-2023-galderma-to-share-latest-data-demonstrating-high-aesthetic-improvement-and-patient-satisfaction-across-its-innovative-portfolio\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230119005530\\\/en\\\/1690638\\\/21\\\/GALDERMA_LOGO_BLACK_RGB.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/imcas-2023-galderma-to-share-latest-data-demonstrating-high-aesthetic-improvement-and-patient-satisfaction-across-its-innovative-portfolio\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/imcas-2023-galderma-to-share-latest-data-demonstrating-high-aesthetic-improvement-and-patient-satisfaction-across-its-innovative-portfolio\\\/\",\"name\":\"IMCAS 2023: Galderma to Share Latest Data Demonstrating High Aesthetic Improvement and Patient Satisfaction Across Its Innovative Portfolio - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/imcas-2023-galderma-to-share-latest-data-demonstrating-high-aesthetic-improvement-and-patient-satisfaction-across-its-innovative-portfolio\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/imcas-2023-galderma-to-share-latest-data-demonstrating-high-aesthetic-improvement-and-patient-satisfaction-across-its-innovative-portfolio\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230119005530\\\/en\\\/1690638\\\/21\\\/GALDERMA_LOGO_BLACK_RGB.jpg\",\"datePublished\":\"2023-01-20T06:04:14+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/imcas-2023-galderma-to-share-latest-data-demonstrating-high-aesthetic-improvement-and-patient-satisfaction-across-its-innovative-portfolio\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/imcas-2023-galderma-to-share-latest-data-demonstrating-high-aesthetic-improvement-and-patient-satisfaction-across-its-innovative-portfolio\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/imcas-2023-galderma-to-share-latest-data-demonstrating-high-aesthetic-improvement-and-patient-satisfaction-across-its-innovative-portfolio\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230119005530\\\/en\\\/1690638\\\/21\\\/GALDERMA_LOGO_BLACK_RGB.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230119005530\\\/en\\\/1690638\\\/21\\\/GALDERMA_LOGO_BLACK_RGB.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/imcas-2023-galderma-to-share-latest-data-demonstrating-high-aesthetic-improvement-and-patient-satisfaction-across-its-innovative-portfolio\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"IMCAS 2023: Galderma to Share Latest Data Demonstrating High Aesthetic Improvement and Patient Satisfaction Across Its Innovative Portfolio\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"IMCAS 2023: Galderma to Share Latest Data Demonstrating High Aesthetic Improvement and Patient Satisfaction Across Its Innovative Portfolio - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/imcas-2023-galderma-to-share-latest-data-demonstrating-high-aesthetic-improvement-and-patient-satisfaction-across-its-innovative-portfolio\/","og_locale":"en_US","og_type":"article","og_title":"IMCAS 2023: Galderma to Share Latest Data Demonstrating High Aesthetic Improvement and Patient Satisfaction Across Its Innovative Portfolio - Pharma Trend","og_description":"Galderma will share exciting results from the Sculptra\u00ae Cheek Wrinkle study showing the long-lasting effectiveness and safety of Sculptra, as well as high aesthetic improvement and patient satisfaction over two yearsi The company will also present 10 research posters, including positive outcomes from the Alluzience\u00ae STAR study. This study shows high patient satisfaction and investigator ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/imcas-2023-galderma-to-share-latest-data-demonstrating-high-aesthetic-improvement-and-patient-satisfaction-across-its-innovative-portfolio\/","og_site_name":"Pharma Trend","article_published_time":"2023-01-20T06:04:14+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230119005530\/en\/1690638\/21\/GALDERMA_LOGO_BLACK_RGB.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/imcas-2023-galderma-to-share-latest-data-demonstrating-high-aesthetic-improvement-and-patient-satisfaction-across-its-innovative-portfolio\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/imcas-2023-galderma-to-share-latest-data-demonstrating-high-aesthetic-improvement-and-patient-satisfaction-across-its-innovative-portfolio\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"IMCAS 2023: Galderma to Share Latest Data Demonstrating High Aesthetic Improvement and Patient Satisfaction Across Its Innovative Portfolio","datePublished":"2023-01-20T06:04:14+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/imcas-2023-galderma-to-share-latest-data-demonstrating-high-aesthetic-improvement-and-patient-satisfaction-across-its-innovative-portfolio\/"},"wordCount":1871,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/imcas-2023-galderma-to-share-latest-data-demonstrating-high-aesthetic-improvement-and-patient-satisfaction-across-its-innovative-portfolio\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230119005530\/en\/1690638\/21\/GALDERMA_LOGO_BLACK_RGB.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/imcas-2023-galderma-to-share-latest-data-demonstrating-high-aesthetic-improvement-and-patient-satisfaction-across-its-innovative-portfolio\/","url":"https:\/\/pharma-trend.com\/en\/imcas-2023-galderma-to-share-latest-data-demonstrating-high-aesthetic-improvement-and-patient-satisfaction-across-its-innovative-portfolio\/","name":"IMCAS 2023: Galderma to Share Latest Data Demonstrating High Aesthetic Improvement and Patient Satisfaction Across Its Innovative Portfolio - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/imcas-2023-galderma-to-share-latest-data-demonstrating-high-aesthetic-improvement-and-patient-satisfaction-across-its-innovative-portfolio\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/imcas-2023-galderma-to-share-latest-data-demonstrating-high-aesthetic-improvement-and-patient-satisfaction-across-its-innovative-portfolio\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230119005530\/en\/1690638\/21\/GALDERMA_LOGO_BLACK_RGB.jpg","datePublished":"2023-01-20T06:04:14+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/imcas-2023-galderma-to-share-latest-data-demonstrating-high-aesthetic-improvement-and-patient-satisfaction-across-its-innovative-portfolio\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/imcas-2023-galderma-to-share-latest-data-demonstrating-high-aesthetic-improvement-and-patient-satisfaction-across-its-innovative-portfolio\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/imcas-2023-galderma-to-share-latest-data-demonstrating-high-aesthetic-improvement-and-patient-satisfaction-across-its-innovative-portfolio\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230119005530\/en\/1690638\/21\/GALDERMA_LOGO_BLACK_RGB.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230119005530\/en\/1690638\/21\/GALDERMA_LOGO_BLACK_RGB.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/imcas-2023-galderma-to-share-latest-data-demonstrating-high-aesthetic-improvement-and-patient-satisfaction-across-its-innovative-portfolio\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"IMCAS 2023: Galderma to Share Latest Data Demonstrating High Aesthetic Improvement and Patient Satisfaction Across Its Innovative Portfolio"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53128","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=53128"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53128\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=53128"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=53128"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=53128"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}